Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have to admit I'm disappointed they issued 5 million shares for measly $50K 0.011...noteholder made a killing on the 0.04+ run in September...thought they would've converted at a higher price.
Need that debt to go down hard to do that when they keep converting around 0.011.
Sometime between yesterday evening and today.
What 8k, link please?
When did the 10k come out?
Think he meant 10K. It is audited so that’s good news. They seem to intend on keeping their QB status alive.
What 8k, link please?
Per 8K company is alive. Still in business. 2024/2025 will be huge!
Many possibilities with this company!!!
And with a 28mil OS….
Looking forward to seeing a nice run on the 10K.
No it hasn’t been updated. Nothing has been updated for a year…. Although the last 10q showed $300k revenue for the first time, but no pr.
I was looking over the website for the first time in months and it seems to have been updated in several places, like the
CLINICAL PATH section, anyone else notice the updates?
I think it’s moving because the 10K is due to drop tomorrow.
10k tomorrow and not usually late on filings.
I’m curious how much money they booked this time? And about the acquisition? Any developments????
News coming? Holding my shares tight :)
Patience will pay
Market Cap Market Cap
339,736
11/24/2023
Authorized Shares
900,000,000
11/24/2023
Outstanding Shares
28,311,352
11/24/2023
Restricted
733,640
11/24/2023
Unrestricted
27,577,712
11/24/2023
Held at DTC
27,567,900
11/24/2023
Float
4,196,841
05/26/2023
The only thing going on is that the price per share has been holding above a penny.... for quite sometime. Just need a catalyst
With the war it could hover around .01
Thanks. Ya one day, but it’s really working with only 2k shares traded lol
Not going anywhere without news
Cnbx will have its day. Found a cnbx 2.0 a few days ago too. QB no news pharmas are the play right now imo.
Market Cap Market Cap
452,982
10/27/2023
Authorized Shares
900,000,000
10/27/2023
Outstanding Shares
28,311,352
10/27/2023
Restricted
733,640
10/27/2023
Unrestricted
27,577,712
10/27/2023
Bought for my wife's acct years ago. It's just down 99.99% :(
Cnbx, speak…….
Whoooopiii yay for them...
At some point there has to be some good news to release here...I just hope the lab survives in Israel...my only concern atm.
Working on uplisting?... No dilution!
QB and SEC current, cooking in the silence. When they speak I expect greater highs quick imo
Flippers done….Just waiting….
Operating in both US and Israel. Their main drugs have already been developed with so much more in the pipeline.
My guess is there’s something major going on with the stem cell acquisition that excelled them into cahoots with a big pharma. Which is the reason for a year of silence?….is that silence is about to break$?
The acquisition was a major deal combining Cnbx technology and stem cells together. Interesting how they gave zero details about. Then 1year of silence….
Market Cap Market Cap
438,826
10/12/2023
Authorized Shares
900,000,000
10/13/2023
Outstanding Shares
28,311,352
10/13/2023
No.
No dilution….
Outstanding Shares
28,311,352
10/13/2023
Typed too fast “Israel will be last”.
israeli ceo is too busy hiding from bombs...dont expect news for months minimum
Hard one to speculate. Israel will last, shrugs.
I own 3 stocks with Israeli ties....
Not sure if that's a good thing
the pos diluter just keeps selling :(
Me too. Good foresight. Flippers just get by….
I find it funny that ask stacking 0.018 wasn't there 2 hours ago but is now lol
Someone is buying up the low priced shares today.
If I had more funds I would be buying some also.
Followers
|
182
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7478
|
Created
|
11/29/09
|
Type
|
Free
|
Moderators |
Outstanding: 4,966,197
Float: 4,196,841
Bringing Cannabinoid Diagnostics to Personalized Cancer Care
Cannabics Pharmaceuticals Inc. (CNBX), a U.S-based public company, is dedicated to the development of personalized diagnostic tools, aimed to provide supportive data for practitioners and patients regarding cannabinoid based therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations. Cannabics engages in delivering the maximum amount of supportive data for cancer patients and their doctors, utilizing advanced screening systems and personalized bioinformatics tools.
Cannabics SR' Capsules, Technology Description - Route of administration
There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy.
The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.
The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process. The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.
Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.
Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."
The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.
The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :
https://clinicaltrials.gov/ct2/show/NCT02359123
"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.
http://www.cannabics.com/investors
Market Value1 | $72,404,107 | a/o Jan 13, 2017 | |
Authorized Shares | 900,000,000 | a/o Dec 30, 2016 | |
Outstanding Shares | 107,265,344 | a/o Dec 30, 2016 | |
-Restricted | 90,368,887 | a/o Dec 30, 2016 | |
-Unrestricted | 16,896,457 | a/o Dec 30, 2016 | |
Held at DTC | Not Available | ||
Float | 14,295,638 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
Market Value1 | $37,994,466 | a/o Oct 28, 2016 | |
Authorized Shares | 900,000,000 | a/o Jul 09, 2015 | |
Outstanding Shares | 107,026,665 | a/o Jun 30, 2016 | |
-Restricted | Not Available | ||
-Unrestricted | Not Available | ||
Held at DTC | Not Available | ||
Float | 18,737,071 | a/o Jun 30, 2016 | |
Par Value | 0.0001 |
PER IHUB MGMT
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |